Challenges in drug development process // Drug Repurposing

Challenges in drug development process

When Patricio O'Donnell started his lab in 1997 at Albany Medical College in New York, schizophrenia research seemed to be moving forward after a long period of stagnation.

Janssen Research & Development

Rodents are used to test drugs designed to correct cognitive deficits in people with schizophrenia.

For several decades, attention had focused on the idea that the disease was caused by elevated dopamine levels in the brain, particularly in the striatum, a nugget of brain tissue nestled under the cortex. But by the 1990s, the dopamine hypothesis was proving inadequate to fully explain the disease. In vivo imaging with computed tomography and magnetic resonance imaging, and data from post-mortem studies in people with schizophrenia, pointed to cortical effects and implicated other neurotransmitter systems, such as glutamate and serotonin. Biologists were also learning to create transgenic mouse models of the disease, providing a set of tools with which to investigate genetic and aetiological factors.

This proliferation of ideas opened the doors to fresh avenues of investigation, as well as new ways of modelling the disease in animals. The classical rodent model for schizophrenia had involved administering amphetamine — which ramps up dopamine levels in synapses and can cause hallucinations and delusions in people — and then measuring behaviours such as hyperactivity or passive avoidance. Researchers then began using other pharmacological agents, such as phencyclidine (PCP) and ketamine, which interfere with the glutamate receptor NMDA, or knocking out specific genes, such as those that code for neurotransmitter receptors.

O'Donnell was captivated by one particular approach that entails chemically damaging part of the hippocampus in newborn animals. Rodent pups who receive this intervention initially appear normal, but they later become socially withdrawn and overly responsive to stress, and their cortices show some of the physiological changes observed in post-mortem tissue. These findings reflect the now-accepted hypothesis that schizophrenia is a developmental disorder. “What made it attractive to me was that even though the lesion was done really early in development, all these behavioural abnormalities didn't emerge until adolescence, ” says O'Donnell, now vice-president and head of psychiatry and behavioural disorders at Pfizer Neuroscience in Cambridge, Massachusetts.

Attempts to mimic the symptoms or underlying physiological effects of schizophrenia have multiplied since then. As genome-wide association studies began pinpointing genes associated with the disease (see 'Unravelling complexity', page S6), researchers have knocked out or perturbed those genes in mice. Others have looked at environmental stressors, such as prenatal infections, early social isolation or stress, or lesions, like the ones O'Donnell used in the hypothalamus. And others give animals drugs such as amphetamine, ketamine and PCP. Some researchers have begun combining some of these manipulations — delivering an environmental stressor, for example, to mice lacking a particular schizophrenia-associated gene.

You might also like

Lupus Drug Development
Lupus Drug Development
The challenges of oncology drug development (part 1)
The challenges of oncology drug development (part 1)

Latin American Leaders oppose plan colombia

by jnc

Over 100 Top Latin American Leaders Call on President Bush to Halt “Plan Colombia” at Upcoming Summit of the Americas
President George W. Bush
United States of America
April 16, 2001
Dear President Bush,
As your Administration considers the future direction of U.S. policy towards the Andes, we ask you to suspend and reformulate US support for the implementation of Plan Colombia, placing a greater emphasis on supporting the peace process.
We, the undersigned Latin Americans, know there are no easy answers or quick fixes to Colombia's tragic dilemma of warfare and drug related violence

How Technology Will Defeat Terrorism

by tisktisk

In transit across Manhattan on any given day are some 4 million letters, 3 million people, half a million motor vehicles and their contents, and half a million parcels—any of which may be carrying something lethal. Step by step, cities like New York must now learn to watch and track everything that moves. Airport screening is coming to much of the rest of civilian life; but it will have to be much smoother, faster, more accurate screening than airports have today, or life will just grind to a halt.
However much local governments may yearn for a one-stop federal solution to their new security problems, much of the initiative and innovation will almost certainly be left to them

Peoples Bark News Berkeley

by johnvance

Please visit for news. There are also very good IRCchat rooms that could be utilized.
PBNB Editor
========================================
========================================
Celebrate Black History and Womyn's Herstory every day!
=============================
PRUNE the SHRUB!
ILLEGITIMATE SONOFABUSH!
These ARE available buttons/stickers - check out how to get em' at our
website! all news flashes to
aliun@hotmail.com for publication.
=================
'THERE IS NO WAY TO PEACE, PEACE IS THE WAY' --- A.J. Muste
===============
===============
If you believe that Peoples Bark News Berkeley is an invaluable contribution and an asset to the community, please consider making a donation. We are not tax-deductible. You must make checks out to:
john vance, c/o A First Amendment Center and mail to:
A First Amendment Center
PO Box 48…

Wiley Flow Cytometry in Drug Discovery and Development
Book (Wiley)

The Morning Ledger: Companies Look to Turn the Tables on Proxy Advisers  — Wall Street Journal
Astra cited the potential value of its cancer drugs in development as one of the reasons for rejecting the approach. Tesla's Musk plans to remain CEO into 2018.